New hope for rare immune disorder: first human trial begins
NCT ID NCT07364513
First seen Jan 24, 2026 · Last updated May 02, 2026 · Updated 17 times
Summary
This early-stage study tests a new drug called IMSB301 in people with a rare group of diseases called type 1 interferonopathies, where the immune system is overactive. The main goal is to check if the drug is safe and how it moves through the body. Only 6 participants are being enrolled, and the study is open-label, meaning everyone knows they are getting the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 INTERFERONOPATHIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Children's Hospital at Westmead
RECRUITINGSydney, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.